Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botensilimab, Balstilimab, and SBRT in Colorectal Cancer With Liver Metastasis
NCT07128355Phase 1Recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- May 2026
- Primary completion
- Jan 2027
- Modality
- Monoclonal Antibodies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of botensilimab and balstilimab in colorectal cancer (CRC), sponsored by Massachusetts General Hospital. Primary endpoint: Dose Limiting Toxicities at 60 days. Started May 2026; status: recruiting.
02
Drugs
botensilimabbalstilimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07128355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07128355.